http://koreamatchmaker.com/registration/ Our Korea matchmaking online dating service has helped millions of sexy single korean women to find their perfect match.
On Saturday, May 21, some of the biggest names in the entertainment industry celebrated the 90th birthday of the legendary Tony Bennett at Keep Memory Alive’s 20th annual Power of Love® gala at the MGM Grand Garden Arena in Las Vegas. The star-studded event raised funds and awareness for Cleveland Clinic Lou Ruvo Center for Brain Health and its fight against brain disease including Alzheimer’s, Huntington’s and Parkinson’s diseases, multiple sclerosis and multiple system atrophy.
Highlights from the night included a performance by honoree Tony Bennett and heartfelt tributes by James Corden, Andra Day, Herbie Hancock, Darius Rucker, Jordin Sparks, Steven Tyler and more. Day kicked off the show with her rendition of “Steppin’ Out With My Baby,” while Corden performed his version of “Don’t Get Around Much More.” Later in the evening, Sparks teamed up with pianist Dan Orlando to perform a medley of hits including “The Best Is Yet To Come,” “Alright OK You Win” and “It Don’t Mean A Thing.” Rucker treated guests to hit single “Sunny Side of The Street,” before Hancock took the stage to perform “Chameleon” and “Cantaloupe Island.” Tyler joined the elite ensemble to perform “Smile” with jazz trumpeter Chris Botti before singing Aerosmith classic “I Don’t Want To Miss A Thing.” The man of the evening, Bennett, performed numerous hits including “Watch What Happens” and “How Do You Keep The Music Playing.” To close the show, the entire cast sang Bennett “Happy Birthday” and presented him with a celebratory cake. In addition to musical icons, celebrity supporters who also attended the event included Quincy Jones, Brad Garrett, Steve Schirripa and Chazz Palminteri.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842951-keep-memory-alive-tony-bennett/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
